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Within the era of molecularly targeted anticancer agents, it has become increasingly important to provide proof of mechanism as
early on as possible in the drug development cycle, especially in the clinic. Selective activation of apoptosis is often cited as one of the
major goals of cancer chemotherapy. Thus, the present minireview focuses on a discussion of the pros and cons of a variety of
methodological approaches to detect different components of the apoptotic cascade as potential biomarkers of programmed cell
death. The bulk of the discussion centres on serological assays utilising the technique of ELISA, since here there is an obvious
advantage of sampling multiple time points. Potential biomarkers of apoptosis including circulating tumour cells, cytokeratins and
DNA nucleosomes are discussed at length. However, accepting that a single biomarker may not have the power to predict proof of
concept and patient outcome, it is clear that in the future more emphasis will be placed on technologies that can analyse panels of
biomarkers in small volumes of samples. To this end the increased throughput afforded by multiplex ELISA technologies is discussed.
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A biomarker is a characteristic objectively measured and evaluated
to indicate normal or pathogenic biological processes or pharma-
cologic response. Its potential to enhance translational science
progress and accelerate drug development is becoming recognised.
Nowhere is this more pertinent than in the complex arena
of anticancer drug development, where the rate of compound
attrition is high and success rates in the clinic are low (Kola and
Landis, 2004). Biomarkers may facilitate rational decision-making
during drug discovery and in pre-clinical drug evaluation (Collins
and Workman, 2006). In addition, pharmacodynamic biomarkers
allow real-time monitoring of drug efficacy and identify early signs
of toxicity during clinical drug evaluation, while stratification
biomarkers should facilitate selection of patients most likely to
respond (Ludwig and Weinstein, 2005).
Suppression of apoptosis is a hallmark of human cancer
(Weinstein, 2002) and a desired end point of many targeted
therapies is induction of tumour cell death. Mechanism-based
therapies under clinical evaluation in oncology may directly
induce apoptosis by targeting molecular components of apoptosis
regulatory pathways (Taylor et al, 2006), or do so indirectly,
following drug target modulation that is then coupled to apoptosis.
Either way, application of informative, validated biomarkers of
apoptosis in clinical trials of anti-cancer therapies is urgently
required.
APOPTOSIS
Cell death can occur by mechanisms including necrosis, mitotic
catastrophe and autophagy (Taatjes et al, 2008). However,
apoptotic cell death regulators are currently considered to have
significant potential as targets for cancer therapeutics. Morpholo-
gical changes during apoptosis include plasma membrane bleb-
bing, cell shrinkage, chromatin condensation and formation of
apoptotic bodies (Makin and Dive, 2001). The biochemistry of
apoptosis is summarised in three stages, the activation of initiator
caspases, mitochondrial release of ‘apoptogens’ and finally the
activation of effector caspases, which cleave recognised substrates
to dismantle the dying cell.
Molecularly, apoptosis is activated via either the death-receptor-
mediated extrinsic pathway or the mitochondria-directed intrinsic
pathway. The extrinsic pathway, triggered by ligands binding
plasma membrane death receptors, leads to activation of initiator
caspase 8 (Fas et al, 2006). In certain cell types, this directly
activates effector caspases, such as caspase 3, whereas in others
(and in most cancer cells) caspase 8 can amplify death signalling
by engaging the intrinsic pathway. The latter is controlled by pro-
and anti-apoptotic Bcl-2 family proteins where, upon an apoptotic
stimulus, changes in intrafamily protein interactions at the
mitochondrial surface determine the release of cytochrome c.
Cytosolic cytochrome c activates the apoptosome complex,
initiator caspase 9 and the effector caspases. Caspase cleavage of
cytokeratins (CKs), poly(ADP-ribose) polymerase and activation
of endonucleases (to generate nucleosomal DNA (nDNA)) form a
cascade of irreversible events and lead to the formation of
apoptotic bodies. They also promote exposure of phosphatidylser-
ine on the external surface of the plasma membrane, which allows
phagocyte recognition of the dying cell.
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biomarkers of apoptosis (Figure 1), (Singhal et al, 2005) (Table 1).
However, detection of apoptosis in vivo is challenging; it is
generally asynchronous and the half-life of apoptotic cells in
tissues is short. Thus, time of analysis is critical regarding
the levels of apoptosis detected in patient samples. Apoptosis
kinetics are dependent upon the drug’s mechanism of action, its
pharmacokinetics and critically, the apoptotic threshold of the
cells in question.
APPLICATION OF BIOMARKERS IN CLINICAL TRIALS
Biomarker qualification is the preferred terminology for the
evidentiary procedure of causally linking a biomarker to a
biological process, pharmacodynamic (PD) effect or clinical end
point (Wagner, 2002). This is a lengthy process requiring
retrospective and prospective clinical trials and large population
screening. This duration may not be necessary for biomarkers
intended for early-phase drug discovery (Lee et al, 2005).
Therefore, qualification and method validation requirements
depend upon the inherent assay quantitation and the position of
biomarkers in the spectrum toward the clinical end point
(Cummings et al, 2008). Nonetheless, emphasising on mechanistic
studies at the pre-clinical stage with robust PD biomarker assays
will increase prospects of successful outcomes in the clinic (Sarker
and Workman, 2007).
IDEAL CHARACTERISTICS OF A BIOMARKER
Use of PD biomarkers in early clinical trials extends hypothesis
testing and confirms whether a drug hits a tumour target (proof of
mechanism, POM) and thereafter, the anticipated tumour outcome
is reached (proof of concept, POC). The PD biomarkers compared
before and after drug treatment may reflect changes in drug target
(e.g., protein phosphorylation, direct DNA damage and enzyme
activity), or those distal to target hitting (e.g., downstream
signalling events, changes in gene expression). Cell fate after
target modulation should then be apparent (e.g., changes in
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Figure 1 Schematic diagram of the consequential accumulation of proteins following induction of apoptosis. These biomarker molecules are eventually
released and can be detected in the circulation in patients undergoing therapy.
Table 1 Most commonly described biomarkers of apoptosis can be measured in tissues and blood using a variety of technology platforms
Biomarker Matrix Analysis platform Comment
Activated caspases 2, 3, 7, 8
and 9
Tissue IHC, Elisa, flow cytometry,
cytometric bead arrays
Detection by immunoreaction or substrate/active site interactions
Cytochrome c Tissue, serum ELISA Useful biomarker measured serially in blood samples
Externalised phosphatidylserine Cells ELISA, flow cytometry Measures Annexin binding to externalised ligand. Early apoptosis event
Cytokeratins Tissue, serum plasma ELISA, IHC, Flow cytometry Useful biomarker measured serially in blood samples
Nucleosomal DNA Tissue, serum ELISA, DNA array, PCR Nucleosomal DNA can be measured serially in serum samples.
Extracted DNA can be analysed using PCR
Apo-1/Fas, Fas ligand (sFasL) Serum, follicular fluid, cells ELISA, flow cytometry, IHC Expressed on B and T cells as well as in normal and tumour tissue
Bcl-2/Bcl-xl/Mcl-1 Cells, tissue IHC, ELISA, flow cytometry Overexpression contributes to chemo-resistance.
p53, phospo-p53, p21
wafi,
pH2AX
Cells, tissues IHC, flow cytometry, ELISA Activation and stabilisation of these proteins informs on DNA damage
and repair
IHC¼immunohistochemistry; PCR¼polymerase chain reaction. Currently, ELISA platforms and flow cytometry offer the highest throughput for clinical trial use.
Biomarkers of apoptosis
TH Ward et al
842
British Journal of Cancer (2008) 99(6), 841–846 & 2008 Cancer Research UKproliferation, apoptosis or angiogenesis) (Hidalgo, 2004). Bio-
markers measured in tumour and/or surrogate body fluids
encompass a broad range of molecules (proteins, nucleic acids,
lipids and sugars) as well as circulating intact cells. An ideal
biomarker should provide a minimally invasive/non-invasive
indirect continuous readout of disease/drug activity.
Ideal biomarkers should therefore aspire to the following
criteria:
  Specificity for the biological process/target
  Accurately quantifiable in clinical samples with sufficient
dynamic range to detect change upon drug treatment
  Provide a rapid, reliable and robust measurement
  Validateable and validated to internationally recognised
standards
  Exhibit little overlap in levels between untreated patients and
treated patients
  Have baseline levels not subject to wide variations between
patients
  Have levels that correlate with the total burden of disease and
unaffected by unrelated conditions
  Have levels that correlate closely with the proximal or distal
effects of therapy, thereby aiding POM or POC
  Measurable in a readily obtainable clinical sample
The best approach to chart the progress of apoptosis in a
patient’s tumour directly before and after a therapeutic intervention
would be to interrogate serial tumour biopsies. However, this is
usually impractical and unacceptable to the patient. Biomarker
analysis procedures that are less invasive must be adopted,
including biomedical imaging and detection in more readily
obtainable samples such as biological fluids. As the scope of
imaging technologies expands and relationships between drug-
induced changes in blood-borne biomarkers and tumour images
(that detect changes in volume, metabolic activity, and so on) are
revealed, a more comprehensive understanding of drug effects in
tumours will emerge. There is no ideal biomarker that meets all the
above criteria under all circumstances. This is precisely because
fulfilling such criteria is so demanding that assays used to measure
biomarkers should be validated to exacting standards. Panels of
biomarkers must be defined that will in themselves collectively meet
these exacting requirements. Such panels may represent a series of
single measurements or, more likely, as modern technological
platforms emerge, by multiplex measurements. The use of such
multiplex measurements will itself generate significant problems for
method validation, such as crossreactivity, interference, sensitivity
and stability. Such issues will in turn require more complex,
although no less stringent, validation strategies. The gulf between
technology and the successful deployment of biomarkers in clinical
trials is narrowing rapidly, although clinical pharmacology
laboratories face significant challenges in implementing biomarker
studies in early clinical trials (Cummings et al, 2004).
WHAT WE CAN CURRENTLY MEASURE
Serial tumour sampling is rarely obtained in early-phase clinical
trials, although fixed tissue from diagnosis is often available. As a
consequence, the broad utility of tissue biomarkers is limited to
prognosis in the first instance and resistance to therapy in the
second. Resistance to therapy is often the result of multiple
mechanisms such as overexpression of anti-apoptotic proteins,
such as Bcl-2 family members (Bcl-2, Bcl-xL, Bcl-w, Mcl-1), or the
inhibitors of apoptosis proteins (IAPs), such as survivin or XIAP. In
addition, downregulation or mutation of pro-apoptotic proteins,
such as Bax, caspase 8, death receptors, p53/p73/p21wafI, as well as
alterations in NF-kB expression/activity can all contribute to
chemoresistance (Igney and Krammer, 2002). Most, if not all, of
these proteins have been detected in tissues using immunohisto-
chemistry. However, there are now also many ELISA and cytometric
bead-based assays available. The above listed markers remain
potential predictors of therapy response rather than truly PD
biomarkers, which change in response to therapy. Many of the
established caspase substrates are potentially good candidate POC
biomarkers of apoptosis that can be measured by immunohisto-
chemistry and ELISA-based assays (e.g., cleaved poly(ADP-ribose)
polymerase and cleaved caspase 3). However, if the products of the
apoptotic cascade are released into the circulation of cancer patients
following therapeutic intervention, they can be more readily
measured serially and therefore dynamically. Cytokeratins form
approximately 5% of intracellular proteins; therefore, by measuring
these, even small numbers of apoptotic cells should be detectable
(Biven et al, 2003). Specific ELISAs have been developed to quantify
CK18 and/or CK19 (e.g., tissue polypeptide antigen, tissue polypep-
tide-specific antigen and CYFRA21-1) (Holdenrieder et al, 2006).
These assays are not specific to apoptosis, as necrosis also leads to
the release of intact soluble CKs. The M30 apoptosense ELISA uses
an antibody to a caspase-cleaved neo-epitope on CK18, whereas the
M65 ELISA detects both intact and cleaved soluble CK18. The
combined use of M30 and M65 offers potential to dissect
mechanisms of cell death in cancer patients (Kramer et al,2 0 0 4 ) .
Apoptotic endonucleases preferentially cleave DNA between
nucleosomes, and the resultant oligonucleosomes are detectable in
serum where histones partially protect DNA from further nuclease
degradation. In healthy subjects, nDNA has a short half-life;
however, their levels are elevated in cancer patients suggesting
high levels of production, altered catabolism or both (Holdenrie-
der et al, 2006), and ELISA assays can detect nucleosomes in
cancer patient sera. Since CKs do not provide any information on
cell death from non-epithelial cells, their combined use with nDNA
provides a biomarker panel to assess caspase-dependent and -
independent cell deaths of all nucleated cells.
Such assays are being integrated into trials of pro-apoptotic
therapies as POC biomarkers (Cummings et al, 2006). Although these
biomarkers are elevated in cancer patients, they are not sufficiently
specific for diagnosis. However, high levels appear to be associated
with poor prognosis in certain tumour types, probably reflecting
tumour burden. Indeed tissue polypeptide antigen and tissue
polypeptide-specific antigen have been used as tumour markers
(Holdenrieder et al, 2006; Ulukaya et al, 2007), and increases in their
levels after chemotherapy may be associated with therapeutic
response, although this has not been consistently reproduced
(Kramer et al, 2004; Olofsson et al, 2007; Ulukaya et al, 2007). In
one of the largest studies, nDNA and CYFRA21-1 were measured in
311 patients with NSCLC receiving chemotherapy (Holdenrieder
et al, 2006). Changes in nDNA and CYFRA21-1 predicted response
independently from stage and performance status. These assays in
combination demonstrated 100% specificity for response with a
sensitivity of 29%, suggesting that they add clinically meaningful
information to patient management. Clearly, panels of multiple
validated biomarkers specifically tailored to particular treatment
regimes or disease groups are the way forward. Currently, we are
using existing tumour markers to follow dynamic fold changes in
biomarker levels in response to therapy, a hitherto little explored
approach. However, new biomarkers as predictors of response as well
as patient survival are urgently needed. Such novel biomarkers will
need to be tested in large trials with full clinical data available and
follow-up, and the biomarker data subjected to rigorous statistical
evaluation before implementation into routine clinical practice. The
goal of stratifying patients based on biomarker expression is yet to be
fulfilled and is an exciting goal for moving ahead.
BIOMARKERS: THE CLINICAL CHALLENGES
Cancer is complex and it is increasingly recognised that tumour
cells are rarely addicted to a single pathway, and therefore
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durable remissions due to plasticity, redundancy and feedback
mechanisms within molecular signalling pathways. Likewise,
considering ‘biomarkers’ as a generic term is an oversimplifica-
tion. Biomarkers that identify at-risk individuals, detect disease
earlier, determine prognosis, detect recurrence/metastases and
predict or monitor response/toxicity to treatment are needed
(Voorzanger-Rousselot and Garnero, 2007). It is essential that
targeted therapies and their associated biomarkers co-evolve.
One key barrier is the lack of high-quality reference material to
define biomarker normality, as before you can detect an abnormality,
it is essential to know the normal range of a biomarker. Moreover, to
get an understanding of the biomarker dynamic range in tumours
(given tumour heterogeneity) requires comprehensive international
databases of healthy individual and cancer patient samples, collected
by standardised methods at multiple time points, analysed retro-
spectively and prospectively, using validated protocols with quality
controls combined with long-term clinical data. Currently, due to
interinstitutional variability, this is barely achievable within a nation.
Only with this international co-operation, may a consensus of
‘normal’ be obtained and biomarkers discovered, validated to
identify false-positives and -negatives, and qualified rapidly.
In current practice, it is extremely rare that biomarker changes
accurately represent all of the effects of a therapy on the clinical
outcome and, thus, it is essential that biomarker qualification
does not distract from robust clinical end points. Finally, as
stated above, although many biomarkers correlate statistically
with disease end points, this does not automatically prove clinical
usefulness (Kattan, 2003). Before integration into the busy clinic,
‘novel’ biomarkers must demonstrate added value beyond that
which is already available.
NEW TECHNOLOGY PLATFORMS: THE PROMISE OF
THE FUTURE
Protein microarray technology is a rapidly evolving field, driven by
the need for high-throughput methodology to measure multiple
biomarkers in clinical samples. Nearly all the fully tested and
characterised protein microarrays are based on antibody technol-
ogies. These multiplex platforms have become widely used in the
exploratory research arena. To date, three main formats exist:
substrate-anchored sandwich ELISA, liquid-based bead assays and
protein arrays. Although much effort has been invested in
optimisation and instrumentation, these techniques are still only
at an early stage of development for use in clinical trials.
ELISAs use an immobilised antibody to capture a soluble ligand,
with subsequent detection of captured ligand by a second antibody
linked to a reporter molecule. Multiplex plate-based sandwich
ELISAs, such as the MSD Mesoscale
s (Gaithersburgh, MD, USA)
and SearchLight
s (Fischer Scientific, Pittsburgh, PA, USA)
chemiluminescent arrays are capable of quantification of up to
16 different proteins in multi-well plates. This approach has the
advantage that a greater number of analytes can be measured in
the same or smaller volume of blood than a conventional single-
plex ELISA. This economic use of samples represents a significant
saving in both cost and blood/tumour lysate volumes (Nielsen and
Geierstanger, 2004). In bead-based assays, such as Luminex and
Bead array, capture antibodies are conjugated to polystyrene beads
that are uniquely tagged with a combination of two fluorescent
dyes. Such dye combinations represent a unique signature for
each bead. A second detection antibody tagged with a common
fluorochrome is used to quantify the amount of analyte bound
to each bead. Detection and quantification are achieved using
conventional flow cytometry or dedicated bead-based bioanaly-
sers. Multiplex assays can be created by mixing bead sets with
different conjugated capture antibodies to simultaneously test for
many (up to 50 or more) analytes in a single clinical sample (Elshal
and McCoy, 2006). There are several substantial differences
between multiplex platforms in current use and little published
work exists regarding validating the relative performances of each
platform. Most of the comparisons that have been published to
date compare the ‘gold standard’ single-plex ELISA assay to that of
a new multiplex system. Comparisons between multiplex and
single-plex platforms tend to show good correlations (0.6–0.96).
Moreover, both intra- and interassay variations are generally less
than 16% (Elshal and McCoy, 2006). The main stumbling block
with such comparisons is the source of the antibodies used to
capture the analyte, the nature of the capture surface, cross-
reactivity of the antibodies and heterophilic reactions within the
physiological matrix. If comparisons are made between platforms
that use identical antibody pairs and detection reagents, correla-
tions tend to be tight. However, even in this scenario, the nature of
the substrate is important. Bead-based assays tend to have a lower
available surface area to react with analytes than do microspot-
based assays. As they flow through the analysis system, beads often
have only a half or less of their surface area presented to the signal
detector at any time. The uniform, high-density signal from
microspots leads to lower levels of detection but higher levels of
sensitivity, when compared with bead-based platforms. Despite
these issues, multiplex assays are still capable of detection in the
analyte nanogram range and a number of multiplex assay
platforms have been approved by the FDA (Ling et al, 2007).
Protein arrays consist of a large number of regularly arranged
discrete microspots of capture molecules, which are transferred
onto a solid support using spotting robots. Spotted capture
molecules may also be conjugated to fluorescent beads, thereby
enabling existing cytometric bead-based technologies to capture
nucleic acids, proteins and soluble receptors/ligands. Purified
recombinant proteins, antibodies, antibody fragments, aptamers,
peptides, nucleic acids or complex protein extracts have all been
used as capture molecules. These arrays measure relative protein
abundance and are analogous to the DNA arrays commonly used
in expression profiling. Comparison of different biological samples
in this way is increasingly important in the discovery of potential
biomarkers and new targets for therapies.
The development of stable, intensely fluorescent reporter
molecules, such as quantum dots, will enhance the multiplexing
capacities of protein microarrays (Kersten et al, 2005).
Currently, analysis of a single analyte with a single assay is the
predominant method applied to most clinical trials. However, once
validation strategies have proved multiplex assays to be as robust,
reliable and reproducible as single-plex assays, they are destined to
comprise a significant part of clinical trial activities. Potentially, these
technologies could rapidly trawl through a subset of trial samples to
identify the most informative biomarkers to be implemented in the
context of that trial. However, one must always bear in mind that
regardless of the method chosen to measure biomarkers (singly or
multiply), they still exist in a complex biological matrix where they
have the potential to interact. More importantly, the rate at which
individual biomarkers degrade within such a matrix may vary
significantly between biomarkers. Such possibilities mean that analysis
of clinical samples should take place as soon as possible following
collection. When the path for regulatory compliance for these assays is
defined, the development of multiplex systems should accelerate and
these approaches should be widely taken up for clinical trials.
SERIAL COLLECTION OF CIRCULATING TUMOUR
CELLS: A CELL-BASED APOPTOTIC BIOMARKER?
Circulating tumour cells (CTCs) have been detected in the
peripheral blood of patients with solid carcinomas (Cristofanilli
et al, 2004). Although the development of apoptotic biomarkers
has been predominantly focused on the molecular level, decreased
CTC numbers may represent an apoptosis-associated biomarker.
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morphological and molecular characterisation of CTCs can be
carried out in great detail. Accumulating evidence shows that CTCs
represent a heterogeneous cell population, among which there
exist both apoptotic cells and viable cells with metastatic potential.
At the cellular level, the change of CTC number pre- and post-
treatment correlates well with patient response to treatment
in several cancer types (Cristofanilli et al, 2004). Persistence of
CTCs 3–4 weeks following therapy strongly suggested that the
patients are relapsing with drug-resistant disease and additional
chemotherapy would be futile (Cristofanilli et al, 2004). At the
level of morphology, incorporating Wright–Giemsa staining into
the protocol allows fibre-optic array scanning technology to be
applied. This approach has shown that CTCs detected from widely
metastatic breast cancer patients exhibited early and late apoptotic
changes (Marrinucci et al, 2007). Further studies have shown that
circulating breast cancer cells are frequently apoptotic based on
CK staining pattern, nuclear condensation and DNA strand-breaks
(Mehes et al, 2001), and caspase-cleaved CK18 was detected in
circulating prostate tumour cells (Larson et al, 2004). In contrast to
CT scans, which are expensive, and biopsies, which are difficult to
serially collect, the assessment of CTCs provides a readily accessed
and cheaper biomarker. Such biomarkers inform on early dynamic
changes in the tumour population, which in turn help to evaluate
therapeutic response and provide POM for novel pro-apoptotic
drugs. Isolation of viable, intact CTCs in sufficient purity and
quality may allow informative genomic profiling. Although CTCs
may provide a practical useful source of biomarkers, it is not yet
known precisely how they relate to the primary tumour, or which
CTC markers might predict which cells will metastasise. Techno-
logies for isolating CTCs are advancing rapidly and CTCs have a
great potential for biomarker research.
SUMMARY
In the era of molecular targeted agents, cell death pathways have
become key players in drug discovery portfolios. Proteomics can
be seen to be playing an ever-increasing role in both the discovery
and measurement of biomarkers pertinent to cell death pathways.
Apoptosis, therefore, represents not only a vital target in oncology
but also a unique biomarker opportunity hitherto unexploited.
The challenge ahead lies in discovering new biomarkers and
understanding the biology of cellular release of existing apop-
totic biomarkers into the circulation. More complex still is the
relationship between clinical efficacy, biomarker measurement
and overall survival of patients treated with novel molecular
targeted agents. As with genomics, key technology tools are now
available to fully exploit these opportunities and take apoptosis
biomarkers to the forefront of drug discovery and future clinical
trials.
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